Ignalis 100 Tablet

This dual action helps improve glycemic control without causing significant hypoglycemia. Ignalis 100 is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The medication is administered orally once daily, with or without food.

Clinical studies have demonstrated that Sitagliptin effectively lowers HbA1c levels and fasting plasma glucose, contributing to improved long-term glycemic management. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections, while serious side effects are rare but may include pancreatitis and hypersensitivity reactions. Regular monitoring of renal function is recommended, as dose adjustments may be necessary in patients with renal impairment.

Ignalis 100 should be used under medical supervision to optimize diabetes management and minimize complications.